Fortress Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2008
Net Income	-54.52	-68.67	-94.61	-64.7	-46.53	-39.96	Upgrade
Depreciation & Amortization	8.43	8.08	9.35	4.32	3.91	3.48	Upgrade
Share-Based Compensation	17.16	17.03	22.99	19.49	13.45	13.19	Upgrade
Other Operating Activities	-81.46	-92.69	-125.17	-75.64	-54.51	-71.67	Upgrade
Operating Cash Flow	-110.39	-128.23	-179.4	-116.54	-83.68	-94.96	Upgrade
Capital Expenditures	5.94	5.94	-2.59	-4.97	-3.13	-4.75	Upgrade
Acquisitions	5	0	-20	56.86	0	-1.2	Upgrade
Change in Investments	0	0	0	0	0	17.6	Upgrade
Other Investing Activities	-8.04	-8.04	-0.34	-11.38	-4.04	8.44	Upgrade
Investing Cash Flow	2.9	-2.1	-22.93	40.51	-7.16	20.1	Upgrade
Share Issuance / Repurchase	21.36	24.12	4.53	9.36	46.03	20.38	Upgrade
Debt Issued / Paid	-38.85	-39	48.65	-9.73	-34.12	13.36	Upgrade
Other Financing Activities	55.91	47.62	22.14	149.36	160.5	112.98	Upgrade
Financing Cash Flow	38.41	32.74	75.32	148.99	172.41	146.71	Upgrade
Net Cash Flow	-69.08	-97.59	-127.01	72.97	81.56	71.85	Upgrade
Free Cash Flow	-104.46	-122.29	-181.99	-121.51	-86.81	-99.71	Upgrade
Free Cash Flow Margin	-122.72%	-144.70%	-240.27%	-176.63%	-190.37%	-272.21%	Upgrade
Free Cash Flow Per Share	-6.09	-15.08	-30.72	-22.31	-18.08	-27.34	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).